However, the lack of a clinically significant benefit from FLT3-inhibitors in NUP98::NSD1/FLT3-ITD AML indicates that the NUP98 fusion is a potent leukemic driver with an independent impact on prognosis (Tarlock et al., 2019). Here, FLT3 is linked to acute myeloid leukemia.